Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 13, 2016OncotargetOpen Access

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLuca MalorniSPSilvano PiazzaYCYari Ciani

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Malorni et al. (2016) studied this question.

synapsesocial.com/papers/6a1269b2ea48cb855a34cab2https://doi.org/10.18632/oncotarget.12010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro2009 · 1,421 citations
  2. 2Comprehensive molecular portraits of human breast tumours2012 · 12,649 citations
  3. 3Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer2015 · 101 citations
  4. 4PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016 · 30,894 citations
  5. 5Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer2015 · 1,606 citations